Arena Pharmaceuticals Inc.'s first Phase III trial of obesity drug lorcaserin met all three of its co-primary endpoints, yet the company's shares fell 28 percent on Monday as investors questioned whether the data will be strong enough to secure a partnership and relieve Arena's cash concerns. (BioWorld Today) Read More
